Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Skinvisible Pharmaceuticals announces 99.6% effective transdermal glucose control without patches or needles in a study.

flag Skinvisible Pharmaceuticals has published findings on its transdermal delivery system, Invisicare®, which effectively administers glucose-controlling agents without patches or needles. flag The study showed a remarkable 99.6% delivery rate for GLP-1 formulations over six hours. flag This method may enhance patient compliance and reduce side effects linked to oral medications. flag The company seeks partnerships to advance transdermal obesity therapies and explore wider applications of its technology.

7 Articles

Further Reading